Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 53, Issue -, Pages 88-95Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2018.04.010
Keywords
-
Categories
Funding
- Influenza Centre at the University of Bergen
- Ministry of Health and Care Services, Norway
- Research Council of Norway EU Nanomedicines program (Flunanoair)
- European Union [Uni-vax 601738, EU IMI1 15672]
- K.G. Jebsen Centre for Influenza Vaccine Research
- Bergen Clinical Vaccine Consortium
Ask authors/readers for more resources
Influenza virus causes contagious respiratory illness and remains a major burden on healthcare systems and the economy. Seasonal influenza vaccine is the most cost-effective way to combat the disease. However, underestimation of disease severity and controversy over vaccine safety and effectiveness hampers public confidence in vaccination. Action is needed to restore public confidence and improve vaccine uptake. Tailoring seasonal influenza vaccines according to immune responsiveness and infection/vaccination history of different populations can improve vaccine efficacy and effectiveness. Steady progress has been made in next generation influenza vaccine designs aiming at broad and long-lasting protective immunity in pre-clinical and clinical studies. However, substantial research and regulatory effort is required before reaching the goal of a truly universal vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available